|
|
|
|
||
Positive Phase II. / No wonder we are down .10Do Like / The complete remission and response rate of 60% of IMC-001 significantly outperformed currently available drugs for the treatment, and very rare adverse events of grade 3 or higher also limit concerns over the side effects, making it a leader among PD-L1 drugs. We expect these results to satisfy the criteria for approval.” |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1692 | Re: Positive Phase II. / No wonder we are down .10 | LTHandy | 0 | 12/5/2022 6:23:50 PM |